MacroGenics | MGNX - Current Liabilities


MacroGenics reported $95.94M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Amgen USD 25.5B 547M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Daiichi Sankyo JPY 765.7B 119.32B Jun/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Genmab DKK 1.43B 686M Dec/2025
Geron USD 73.57M 40.25M Mar/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
MacroGenics USD 95.94M 52.82M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Pfizer USD 32.65B 1.7B Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Xencor USD 73.46M 22.45M Mar/2026